Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

2010 • 1,484 citations

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

2006 • 1,296 citations

Prognostic discrimination in "good-risk" chronic granulocytic leukemia

1984 • 989 citations

Prognostic discrimination in "good-risk" chronic granulocytic leukemia

1984 • 919 citations

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

2006 • 539 citations

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

2010 • 473 citations

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

2005 • 280 citations

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

2011 • 144 citations

BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria

2007 • 142 citations

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

2003 • 141 citations

A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response

2007 • 129 citations

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia

2007 • 109 citations

Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.

2005 • 105 citations

Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients

2002 • 57 citations

Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation

2005 • 50 citations

Curing CML with imatinib—a dream come true?

2011 • 32 citations

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

2008 • 22 citations

Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase

2011 • 18 citations

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

2009 • 11 citations

Cited By (0)

Loading...